HitGen 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MIK665 / Novartis, HitGen
2019-000998-23: Study that tested S64315 plus different standard treatments in patients with breast cancer Estudio de Fase I/II de S64315 en combinación con varios tratamientos estándar incluyendo terapia hormonal y agentes citotóxicos en cáncer de mama (CM) localmente avanzado o metastásico

Ongoing
1/2
290
Europe
S64315, S64315 (also referred as MIK665), Concentrate for solution for infusion, Solution for injection, Halaven, Falsodex, Paclitaxel 6mg/mL
Institut de Recherches Internationales Servier, Laboratorios Servier S.L. (Promotor Local)
Locally advanced or metastatic breast cancer. Cáncer de mama metastásico o localmente avanzado, Breast cancer that has come back and spread to the tissues and lymph nodes around the chest, neck and under the breastbone, or that has spread to other parts of the body beyond the original tumor Cáncer de mama que ha progresado y se ha propagado a los tejidos y ganglios linfáticos alrededor del tórax, el cuello y debajo del esternón, o que se ha diseminado a otras partes del cuerpo, Diseases [C] - Cancer [C04]
 
 
NCT04629443 / 2019-004896-38: Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Completed
1/2
17
Europe, US, RoW
S 64315 (also referred as MIK665) and azacitidine
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Acute Myeloid Leukaemia
08/23
08/23
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Terminated
1
37
Europe, Japan, US, RoW
VOB560, S65487, MIK665, S64315
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
07/24
07/24
S65487 / HitGen, Novartis, Servier
CL1-65487-003, NCT04742101 / 2020-003061-19: Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Active, not recruiting
1/2
57
Europe, RoW
S65487 and azacitidine
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Acute Myeloid Leukemia
12/25
12/25
NCT03755154: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Terminated
1
60
Europe, RoW
S65487- initial scheme, S65487 - alternative scheme
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Chronic Lymphocytic Leukemia
11/23
11/23
HG146 / HitGen
HG146, NCT06781567: Clinical Trial of Administered to Participants with Adenoid Cystic Carcinoma

Recruiting
2
140
RoW
HG146, HG146 Capsule
HitGen Inc.
Adenoid Cystic Carcinoma, Head and Neck Cancer
12/28
06/29
HG146-I-CRP-1.0, ChiCTR1800017186: A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in The Treatment of Multiple Myeloma

Not yet recruiting
1
18
 
Different doses of HG146 Capsule
West China Hospital, Sichuan Universty; HitGen Ltd, Company funding
Multiple Myeloma
 
 
NCT03710915: A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

Terminated
1
3
RoW
HG146, HG280146, HG0146, HG280146, HG280146-P1
HitGen Inc.
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
09/22
06/23
NCT04977167: Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Recruiting
1
96
RoW
HG146, PD-(L)1 antibody
HitGen Inc.
Solid Tumor, Lymphoma
12/24
12/24
ChiCTR2100053442: A Phase I Study of HG146 Administered to Subjects with Advanced Malignant Solid Tumors or Lymphoma

Recruiting
1
96
 
HG146 5mg ;HG146 10mg ;HG146 15mg ;HG146 20mg ;HG146 combination with PD-(L)1 inhibitor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chengdu Pioneer Drug Development Co., Ltd., self-funded
Advanced solid tumors or Lymphoma
 
 
ChiCTR2100053046: A Phase I Study of HG146 Capsule Administered to Subjects with Advanced Malignant Solid Tumors or Lymphoma

Not yet recruiting
1
96
 
HG146 5mg ;HG146 10mg ;HG146 15mg ;HG146 20mg
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chengdu Pioneer Drug Development Co., Ltd., Company funding
Advanced solid tumors or Lymphoma
 
 
HG381 / HitGen
ChiCTR2100049629: Phase 1 Study of HG381 Administered to Patients with Advanced Solid Tumors

Not yet recruiting
1
57
 
None
Chinese PLA General Hospital; HitGen Ltd., Company funding
Advanced Solid Tumors
 
 
NCT04998422: A Study of HG381 Administered to Patients With Advanced Solid Tumors

Recruiting
1
57
RoW
HG381, HG381 for Injection
HitGen Inc.
Advanced Solid Tumor
12/25
12/25
TRN-124 / Tris Pharma, HitGen
No trials found
Tuzistra XR (codeine/chlorpheniramine) / Tris Pharma, Aytu BioPharma, HitGen
No trials found
CCP-08 / Tris Pharma, HitGen
No trials found
CCP-08 / Tris Pharma
No trials found
S216096 / HitGen, Servier, Novartis
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MIK665 / Novartis, HitGen
2019-000998-23: Study that tested S64315 plus different standard treatments in patients with breast cancer Estudio de Fase I/II de S64315 en combinación con varios tratamientos estándar incluyendo terapia hormonal y agentes citotóxicos en cáncer de mama (CM) localmente avanzado o metastásico

Ongoing
1/2
290
Europe
S64315, S64315 (also referred as MIK665), Concentrate for solution for infusion, Solution for injection, Halaven, Falsodex, Paclitaxel 6mg/mL
Institut de Recherches Internationales Servier, Laboratorios Servier S.L. (Promotor Local)
Locally advanced or metastatic breast cancer. Cáncer de mama metastásico o localmente avanzado, Breast cancer that has come back and spread to the tissues and lymph nodes around the chest, neck and under the breastbone, or that has spread to other parts of the body beyond the original tumor Cáncer de mama que ha progresado y se ha propagado a los tejidos y ganglios linfáticos alrededor del tórax, el cuello y debajo del esternón, o que se ha diseminado a otras partes del cuerpo, Diseases [C] - Cancer [C04]
 
 
NCT04629443 / 2019-004896-38: Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Completed
1/2
17
Europe, US, RoW
S 64315 (also referred as MIK665) and azacitidine
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Acute Myeloid Leukaemia
08/23
08/23
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Terminated
1
37
Europe, Japan, US, RoW
VOB560, S65487, MIK665, S64315
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
07/24
07/24
S65487 / HitGen, Novartis, Servier
CL1-65487-003, NCT04742101 / 2020-003061-19: Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Active, not recruiting
1/2
57
Europe, RoW
S65487 and azacitidine
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Acute Myeloid Leukemia
12/25
12/25
NCT03755154: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Terminated
1
60
Europe, RoW
S65487- initial scheme, S65487 - alternative scheme
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Chronic Lymphocytic Leukemia
11/23
11/23
HG146 / HitGen
HG146, NCT06781567: Clinical Trial of Administered to Participants with Adenoid Cystic Carcinoma

Recruiting
2
140
RoW
HG146, HG146 Capsule
HitGen Inc.
Adenoid Cystic Carcinoma, Head and Neck Cancer
12/28
06/29
HG146-I-CRP-1.0, ChiCTR1800017186: A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in The Treatment of Multiple Myeloma

Not yet recruiting
1
18
 
Different doses of HG146 Capsule
West China Hospital, Sichuan Universty; HitGen Ltd, Company funding
Multiple Myeloma
 
 
NCT03710915: A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

Terminated
1
3
RoW
HG146, HG280146, HG0146, HG280146, HG280146-P1
HitGen Inc.
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
09/22
06/23
NCT04977167: Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Recruiting
1
96
RoW
HG146, PD-(L)1 antibody
HitGen Inc.
Solid Tumor, Lymphoma
12/24
12/24
ChiCTR2100053442: A Phase I Study of HG146 Administered to Subjects with Advanced Malignant Solid Tumors or Lymphoma

Recruiting
1
96
 
HG146 5mg ;HG146 10mg ;HG146 15mg ;HG146 20mg ;HG146 combination with PD-(L)1 inhibitor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chengdu Pioneer Drug Development Co., Ltd., self-funded
Advanced solid tumors or Lymphoma
 
 
ChiCTR2100053046: A Phase I Study of HG146 Capsule Administered to Subjects with Advanced Malignant Solid Tumors or Lymphoma

Not yet recruiting
1
96
 
HG146 5mg ;HG146 10mg ;HG146 15mg ;HG146 20mg
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chengdu Pioneer Drug Development Co., Ltd., Company funding
Advanced solid tumors or Lymphoma
 
 
HG381 / HitGen
ChiCTR2100049629: Phase 1 Study of HG381 Administered to Patients with Advanced Solid Tumors

Not yet recruiting
1
57
 
None
Chinese PLA General Hospital; HitGen Ltd., Company funding
Advanced Solid Tumors
 
 
NCT04998422: A Study of HG381 Administered to Patients With Advanced Solid Tumors

Recruiting
1
57
RoW
HG381, HG381 for Injection
HitGen Inc.
Advanced Solid Tumor
12/25
12/25
TRN-124 / Tris Pharma, HitGen
No trials found
Tuzistra XR (codeine/chlorpheniramine) / Tris Pharma, Aytu BioPharma, HitGen
No trials found
CCP-08 / Tris Pharma, HitGen
No trials found
CCP-08 / Tris Pharma
No trials found
S216096 / HitGen, Servier, Novartis
No trials found

Download Options